Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MTNB
stocks logo

MTNB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Matinas BioPharma Holdings Inc (MTNB.A) is -0.50, compared to its 5-year average forward P/E of -4.49. For a more detailed relative valuation and DCF analysis to assess Matinas BioPharma Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.49
Current PE
-0.50
Overvalued PE
-0.81
Undervalued PE
-8.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.78
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.04
Undervalued EV/EBITDA
-5.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
93.82
Current PS
0.00
Overvalued PS
283.32
Undervalued PS
-95.68
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

MTNB News & Events

Events Timeline

(ET)
2025-02-06
08:07:26
Cadrenal Therapeutics CMO Douglas Losordo departs, James Ferguson succeeds
select
2025-01-10 (ET)
2025-01-10
16:15:38
Matinas BioPharma receives NYSE noncompliance notice
select
2024-10-31 (ET)
2024-10-31
07:24:22
Matinas BioPharma says MAT2203 partnership negotiations terminated
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
08-18Benzinga
US Stocks Show Varied Performance; Riskified Shares Decline Following Q2 Earnings Report

  • Market Overview: U.S. stocks showed mixed results, with the Dow and NASDAQ slightly up while the S&P 500 fell by 0.03%.

  • Sector Performance: Information technology shares increased by 0.3%, whereas energy stocks dropped by 1.1%.

  • Notable Stock Movements: Riskified shares fell 13% despite meeting earnings expectations, while Propanc Biopharma surged 210% after uplisting to Nasdaq.

  • Global Market Trends: European shares declined, with the eurozone's STOXX 600 down 0.1%, while Asian markets mostly closed higher, led by Japan's Nikkei 225 gaining 0.77%.

[object Object]
Preview
5.0
03-11Newsfilter
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

  • Board Appointments: Matinas BioPharma has appointed Keith Murphy and Edward Neugeboren as independent members of its Board of Directors, effective March 11, 2025, while thanking departing directors Matthew Wikler and Natasha Giordano for their service.

  • Product Development: The company is advancing its oral antifungal treatment MAT2203, which aims to provide a safer alternative to intravenous amphotericin B, having successfully completed a Phase 2 study in HIV patients with cryptococcal meningitis and planning further evaluation in a Phase 3 trial.

[object Object]
Preview
5.0
03-11Business Insider
Matinas BioPharma appoints Murphy, Neugeboren to board of directors

  • Board Appointments: Matinas BioPharma has appointed Keith Murphy and Edward Neugeboren as independent members of its Board of Directors, effective March 11, 2025, while Matthew Wikler, M.D., and Natasha Giordano have stepped down.

  • Committee Changes: Murphy will chair the Nominating and Governance Committee, and Neugeboren will chair the Compensation Committee, with both taking on additional committee roles following the changes.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Matinas BioPharma Holdings Inc (MTNB) stock price today?

The current price of MTNB is 0.751 USD — it has increased 0.13 % in the last trading day.

arrow icon

What is Matinas BioPharma Holdings Inc (MTNB)'s business?

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.

arrow icon

What is the price predicton of MTNB Stock?

Wall Street analysts forecast MTNB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTNB is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Matinas BioPharma Holdings Inc (MTNB)'s revenue for the last quarter?

Matinas BioPharma Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Matinas BioPharma Holdings Inc (MTNB)'s earnings per share (EPS) for the last quarter?

Matinas BioPharma Holdings Inc. EPS for the last quarter amounts to -0.28 USD, decreased -67.06 % YoY.

arrow icon

What changes have occurred in the market's expectations for Matinas BioPharma Holdings Inc (MTNB)'s fundamentals?

The market is revising No Change the revenue expectations for MTNB for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -56.34%.
arrow icon

How many employees does Matinas BioPharma Holdings Inc (MTNB). have?

Matinas BioPharma Holdings Inc (MTNB) has 3 emplpoyees as of December 05 2025.

arrow icon

What is Matinas BioPharma Holdings Inc (MTNB) market cap?

Today MTNB has the market capitalization of 4.81M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free